This week I purchased 8 additional shares AbbVie at a price of $95,85. This brings my total position in AbbVie on 23 shares. With this purchase my yearly estimated dividend income increased with $7,96.
AbbVie is down 23% from the high course of $123,21 reached at the end of January. This is mainly due to Abbvie backing away from pursuing accelerated approval for Rova-T after disappointing mid-stage data in third-line lung cancer. As I didn’t want to put my full monthly deposit in the speculative purchase of Washington Prime Group, I decided to also buy a few additional shares of AbbVie now the share price is down a bit.
Current yield of AbbVie based on a quarterly dividend of $0,96 is 4,0%.